# meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

> **NCT05715814** · PHASE3 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 20 (estimated)

## Conditions studied

- Peritoneal Dialysis Complication
- End Stage Kidney Disease
- Sodium-glucose Co-transporter-2 Inhibitors
- Kidney Dysfunction
- Residual Kidney Function

## Interventions

- **DRUG:** Empagliflozin 25 MG

## Key facts

- **NCT ID:** NCT05715814
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05715814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05715814, "meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05715814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*